RxDoctor Payments Data

Jeffrey Myatt, PA

Medical · Reno, NVNPI 1679850465

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 139 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 45 manufacturers, the largest accounting for just 7.8% — the pattern of someone who eats at a lot of different presentations.

$3,619in general payments, 2019–2025

Across 139 payments — averaging $26.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$282
  • Bayer$203
  • Pfizer$184
  • Novartis$177
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$175
  • Vertos Medical, Inc.$169
  • plus $2K from 39 others

What the payments were for

  • Food & beverage$3,619100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,619 in reported general payments places this provider in the 75th percentile of 250 medical providers in Nevada.

See all medical providers in Nevada

Medicare billing

Part B allowed, 2024
$78,879
Medicare patients
393
Services billed
924

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban297$269,240
EntrestoSacubitril/Valsartan79$93,386
JardianceEmpagliflozin64$76,154
XareltoRivaroxaban72$73,427
FarxigaDapagliflozin Propanediol14$20,349
BrilintaTicagrelor14$9,848
Metoprolol Succinate267$3,954
Atorvastatin Calcium145$2,776
Flecainide Acetate33$2,258
Amiodarone Hcl79$1,733
Diltiazem 24hr Er (Cd)Diltiazem Hcl49$1,668
Midodrine Hcl13$1,549
Losartan Potassium149$1,438
Potassium Chloride86$1,408
Rosuvastatin Calcium36$1,395

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$184$269,240297 claims
NovartisEntresto$177$93,38679 claims
Boehringer IngelheimJardiance$69$76,15464 claims
Johnson & JohnsonXarelto$121$73,42772 claims
AstraZenecaFarxiga, Brilinta$16$30,19728 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 250 medical providers in Nevada.

Other medical in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →